Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

trialsTrialRecruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

A phase 2 trial in pancreatic cancer, run by University of California, Irvine, now recruiting.

Overview Connected2

Overview

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial is a phase 2, randomised interventional study registered as NCT06580002 by University of California, Irvine, with a registry enrolment figure of 75 participants, started 2024-12-02 and due to reach its primary completion in 2027-07. Interventions recorded: Riluzole; Placebo. Conditions listed: Breast Cancer; Sarcoma; Gastric Cancer; Lung Cancer; Head and Neck Cancer; Colorectal Cancer; Ovarian Cancer; Liver Cancer; Genitourinary Cancer; Gynecologic Cancer; Urinary Bladder Cancer; Leukemia; Lymphoid Leukemia; Myeloma Multiple; Prostate Cancer; Pancreas Cancer; Non-hodgkin Lymphoma; Hodgkin Lymphoma; Brain Cancer; Melanoma; Mycosis Fungoides; Kidney Cancer. Primary outcome: Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in cancer survivors experiencing cognitive impairment (CRCI). Sites: United States. No results are recorded here; the registry entry is the source.

Setting

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial

Phase

Phase 2

Sponsor

University of California, Irvine

Registry

Enrolled

75 enrolled

Connected

Similar pages

not linked directly; found by shared links

Trial
The Cancer of the Pancreas Screening-5 CAPS5)Study
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
EUS-RFA PANCARDINAL-1 Trial
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Trial
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.

cancers

1

Pancreatic ductal adenocarcinoma

terms

1

Pancreatic cancer trials open today (registry snapshot and UK sites)

Evidence strength24/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
75 enrolled+9
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources & links

ClinicalTrials.gov NCT06580002

pancreatic-deep-dive

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Pancreatic ductal adenocarcinoma

Machine-readable versions of Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06580002/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06580002.

WebMCP tools registered on this page: onco_search, onco_get_entity.